David Maris

Emergent Biosolutions Inc (NYSE: EBS) Tuesday announced a follow-on U.S. government contract for its smallpox vaccine, ACAM2000. There had been widespread investor concern around the delay in this contract, which has now come in at a much larger size than expected, according to Wells Fargo. The...

Allergan plc (NYSE: AGN) was in for a disappointment with its investigational depression drug candidate Rapastinel, one day after Johnson & Johnson (NYSE: JNJ) secured FDA approval for its treatment-resistant depression drug esketamine. The Analysts Wells Fargo Securities analyst David Maris...

Mylan NV (NASDAQ: MYL) reported disappointing fourth-quarter earnings Tuesday and forecast an earnings shortfall for 2019. The Analysts BMO Capital Markets analyst Gary Nachman maintained an Outperform rating on Mylan shares and reduced the price target from $44 to $40. Cantor Fitzgerald...

Now that the votes have been tallied from the midterm elections, investors are shifting their attention to what the fallout from the midterms will be for the stock market. The early returns on a divided Congress are positive, with the SPDR S&P 500 ETF Trust (NYSE: SPY) trading higher by 2...

Mylan N.V. (NASDAQ: MYL) announced Tuesday that the FDA has approved its Abbreviated New Drug Application for the first generic for Copaxone. Mylan shares were up 19 percent to $38.75. Wells Fargo raised Mylan's price target from $30 to $32, and maintained the rating at Market Perform....

From the looks of it, pharmacy is the place to be. The global sector has hundreds of players, private and public, and household brands like Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK) and Eli Lilly and Co (NYSE: LLY) have long dominated the crowded field. Even so, and despite the...

Amazon.com, Inc. (NASDAQ: AMZN) is reportedly making plans to enter the pharmacy space, and the natural question of “what would happen?” is already being answered. Wells Fargo analyst David Maris conducted a nationwide survey that found five in 10 adults in the U.S. would use or would...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell to a new 52-week low of $10.50 after Bill Ackman sold his stake. Pershing Square, the activist investor's firm, exited its 27.2 million share position at $11. Ackman will also step off the company's board. David Maris of Wells Fargo...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) filed its 2016 10-K on March 3, resulting in pressure on shares. Valeant's disclosures are concerning and the business trends remain weak, which would likely continue to impact the company’s share price, Wells Fargo’s David Maris said in...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Monday that three senior executives will be leaving the company. The executives that will be leaving the company include: Valeant's ex CFO Rob Rosiello, who stepped down in August but remained with the company since. Ari...

Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), saying the new Bloomberg report over potential accounting fraud charges on the company makes the stock further risky for investment. Bloomberg reported that U.S. authorities are investigating potential...

Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) as it believes the Street is underestimating the potential downside from the company's legal woes. Senior analyst David Maris specifically pointed out an insider trading suit filed against Valeant...

On September 16, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) raised the list price by 9.9 percent each of three of its products, according to Medi-Space CDI data. Wells Fargo’s David Maris mentioned that these three products represented on a small portion of Valeant’s sales, with...

Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) saying "things can always get worse" with the stock. "Just when we think everything is bad, they find a way to surprise us to the negative," analyst David Maris said on CNBC....